Data From Tolmar Pharmaceuticals Demonstrate ELIGARD® (leuprolide acetate for injectable suspension) Consistently Suppresses Serum Testosterone Levels in Patients With Advanced Prostate Cancer

NEW ORLEANS, LA – MAY 18, 2015 – Tolmar Pharmaceuticals, Inc. presented data demonstrating that ELIGARD® (leuprolide acetate for injectable suspension), indicated for the palliative treatment of advanced prostate cancer, consistently maintains low serum testosterone (T) levels. ELIGARD is the only LHRH (luteinizing hormone releasing hormone) agonist with the innovative controlled-release ATRIGEL® Delivery System. The data were presented at the 110th Annual American Urological Association Meeting in New Orleans (poster MP73-16).

“Our data demonstrate that ELIGARD with the ATRIGEL® Delivery System achieves and maintains favorable T suppression across all dosing forms,” said lead abstract author Neal Shore MD, FACS, a Society of Urologic Oncology Executive Board member and former member of the National Cancer Institute’s Genitourinary Cancer Scientific Steering Committee.

Data from the analysis of 438 patients in 4 trials over a 6 to 12-month treatment period demonstrate that mean serum T levels in ng/dL at the end of the trials were 6.1 ± 0.4 for the 1-month dose; 10.1 ± 0.7 for the 3-month dose; 12.4 ± 0.8 for the 4-month dose; and 12.6 ± 2.1 for the 6-month dose. 

ELIGARD is available in 1-, 3-, 4-, and 6-month subcutaneous doses that deliver controlled release of leuprolide acetate via the ATRIGEL® Delivery System.

“Because we are a company dedicated to developing innovative pharmaceutical solutions to serve patients in need, our focus is on clinical data that support the efficacy and safety of ELIGARD. Presentation of our data at the 110th Annual American Urological Association Meeting here in New Orleans is a key milestone for us,” said Susan Rodriguez, CEO of Tolmar Pharmaceuticals.   

Tolmar is the inventor, developer, and global manufacturer of ELIGARD. ELIGARD is currently marketed in 67 countries and is supplied by Tolmar’s manufacturing facilities located in Fort Collins, Colorado. In May 2014, Tolmar re-acquired the commercial rights to ELIGARD in the United States and launched Tolmar Pharmaceuticals, a specialty company dedicated to the urology market. As of March 2015, ELIGARD was among the fastest-growing LHRH agonist products in the US, based on quarter-over-quarter trends as reported by IMS Health, IMS DDD MD, 03/2015.

About Tolmar

Tolmar is a fully integrated pharmaceutical company focused on the development, approval, manufacturing, and commercialization of specialty pharmaceutical products.  Tolmar Pharmaceuticals is based in Lincolnshire, Illinois, with Tolmar global headquarters, product development, and manufacturing facilities based in Fort Collins, Colorado. Tolmar Pharmaceuticals has the exclusive distribution rights for ELIGARD in the US and Puerto Rico. ELIGARD is a gonadotropin releasing hormone (GnRH) agonist prescribed for the treatment of advanced prostate cancer, developed and manufactured by Tolmar Inc. “Tolmar” refers to Tolmar Holding Inc. and its wholly owned operating subsidiaries, Tolmar Inc., Tolmar Therapeutics, Inc., and Tolmar Pharmaceuticals, Inc. For more information about the company, please visit Information about ELIGARD is available at Please see Full Prescribing Information for additional important safety information.

# # # #

Media contact:

Amy Speak
Speak Life Science | (617) 420-2461